ISSN: 2167-0846

痛みと緩和のジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • Jゲートを開く
  • Genamics JournalSeek
  • コスモスIF
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

The Use of Exparel in Transversus Abdominus Plane Blocks for Postoperative Pain Control

Kyle Dammann1, Amanda Gifford1, Rodrique Fontem1, and Anna Ng Pellegrino2*

Background: Overuse of opiates in surgical patients has been associated with dependence and poor patient
outcomes. Ultrasound guided transverse abdominal plane (TAP) blocks provide a means for administering nonnarcotic
pain control in patients undergoing abdominal surgery. Exparel is a long acting liposomal bupivacaine with a
duration up to 72 hours. Here we examined the effect of Exparel TAP blocks on postoperative outcomes in a cohort
of surgical patients.
Methods: This study was IRB approved. Patients undergoing open abdominal surgery > 18y/o and ASA 1-3 were
included, and those with allergies to local anesthesia, advanced liver failure, pregnancy, and dementia were excluded.
TAP blocks were performed with ultrasound guidance, and pain scores/outcomes were assessed for five days.
Results: Fifty-two patients underwent open abdominal surgery followed by Exparel TAP blocks (n=26) or standard
opioid therapy (n=26). Fifty two percent were male, mean age was 58 17 years. Exparel treatment resulted in 50%
fewer patients requiring oral morphine equivalents (OME) (61-90) for treatment of severe postoperative pain. Exparel
treatment was associated with decreased length of stay 52 vs 97 days, reduced incidence of ileus (3% vs 27%),
nausea and vomiting (8% vs 42%), readmission (4% vs 12%), and postoperative complications (23% vs 54%). These
findings were also associated with a 27% reduction in cost per admission $18,190 $8700 with Exparel vs $25010
$15423 without Exparel. Exparel reduced the incidence of severe postoperative pain scores by 50% or greater from
POD0- 4.
Conclusion: Exparel TAP blocks improve postoperative outcomes by reducing OME and acute pain scores
associated with reduced length of stay, fewer complications, and average cost per patient. Large randomized
multicenter control trials should investigate whether TAP blocks are similarly effective.